Business
DECN Retains Counsel To File For Two Patents Covering GenUltimate TBG Test Strip And System, Consents To The Publication A White Paper By A Biotech Industry Luminary
DECN Retains Counsel To File For Two Patents Covering GenUltimate TBG Test Strip And System, Consents To The Publication A White Paper By A Biotech Industry Luminary.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"3RD PARTY TESTING AND ANALYSIS OF COMPANY'S GENULTIMATE TBG REVEAL NEVER BEFORE SEEN PRECISION AND ACCURACY AT LEVELS 60% BETTER THAN FDA AND ISO PUBLISHED STANDARDS LOS ANGELES, CA / ACCESSWIRE / September 19, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International markets, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea, expected in late October 2019.DECN announces today that it has completed final development and third party testing of its panacea GenUltimate TBG technology, now added to the company's Quality System, including the Design History, PDR and Design Master Record files. Subsequently, DECN has retained counsel to prosecute applications for two patents as the company moves quickly to secure its diagnostic technology. Work on the patent applications began earlier in September.Keith Berman, CEO of DECN commented, "The latest and final revision of GenUltimate TBG has been provided to the company, and we have enthusiastically accepted TBG into our stable of products. Work will begin immediately to file two patents, the first a patent on the TBG version of the GenUltimate test strip, and a second patent on the TBG system which includes our new Precise! meter."Mr. Berman continues, "The company made what it considered to be a minor change to the TBG chemistry, but this minor change produced breathtaking results, a true "take notice" moment. Our proposed licensing partner has certainly taken notice. With all of the action in the industry focused on Continuous Glucose Monitoring dev...